American Journal of Kidney Diseases

Are we now sisters in the most unlikely of ways? the same way, in your body, humming away Please care for this part of her of molecules in your body. Please care for this kidney, some part of life’s second chance. All this is to say please take care. Part of my sister lives in you too, and forever I am defined as an older sister even if she is gone. But, here you are in the flesh part of her living on.

As the global prevalence of peritoneal dialysis (PD) continues to grow, practitioners must be equipped with prescribing strategies that focus on the needs and preferences of patients. PD is an effective form of kidney replacement therapy that offers numerous benefits to patients, including more flexibility in schedules compared with in-center hemodialysis (HD). Additional benefits of PD include salt and water removal without significant changes in patient hemodynamics.

Rationale & Objective The occurrence and consequences of peritoneal dialysis (PD)-associated peritonitis limit its use in populations with kidney failure. Studies of large clinical populations may enhance our understanding of peritonitis. To facilitate these studies we developed an approach to measuring peritonitis rates using Medicare claims data to characterize peritonitis trends and identify its clinical risk factors. Study Design Retrospective cohort study of PD-associated peritonitis.

Division of Nephrology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Center of Excellence in Kidney Metabolic Disorders, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Dialysis Policy and Practice Program (DiP3), Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand Peritoneal Dialysis Excellence Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand

Kidney disease affects approximately 10% of the population globally, and as of 2019 kidney diseases are the 10th most common cause of mortality worldwide, with 1.3 million deaths annually., Acute kidney injury and kidney failure affect populations with lower socioeconomic status at increased rates. 3 Weldegiorgis M. Smith M. Herrington W.G. Bankhead C. Woodward M. Socioeconomic disadvantage and the risk of advanced chronic kidney disease: results from a cohort study with 1.4 million participants.

Abstract Rationale and Objective Non-Hispanic Black and Hispanic patients present with kidney failure at younger ages than white patients. Younger patients are also more likely to receive transplants and home dialysis than in-center hemodialysis (ICHD), but it is unknown whether racial/ethnic disparities in treatment differ by age. We compared use of kidney replacement therapies between racial/ethnic groups among patients with incident kidney failure, overall, and by age.

Abstract Rationale and Objective Infections cause significant morbidity and mortality for children receiving maintenance hemodialysis (HD). The Standardizing Care to Improve Outcomes in Pediatric ESKD (SCOPE) Collaborative is a quality improvement initiative aimed at reducing dialysis-associated infections by implementing standardized care practices.

Policy Forum highlights aspects of nephrology relating to payment and social policy, legislation, regulation, demographics, politics, and ethics, contextualizing these issues as they relate to the lives and practices of members of the kidney community, including providers, payers, and patients. 1 The National Organ Transplantation Act (NOTA) of 1984 requires that only medical criteria be used in organ allocation decisions.

The most common cause of kidney failure in the United States and across the world is diabetes mellitus (DM). Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in persons with diabetes, and chronic kidney disease (CKD) further increases overall CVD risk. It is important to individualize glycemic targets for patients to maintain glucose levels that will reduce the development and progression of complications while avoiding hypoglycemia.

Background In response to a national call for re-evaluation of the use of race in clinical algorithms, the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) established a Task Force to reassess inclusion of race in the estimation of glomerular filtration rate (GFR) in the United States and its implications for diagnosis and management of patients with, or at risk for, kidney diseases.